A Phase 2 interventional study of Emtricitabine in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 2 sites in South Africa. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2018-04-26.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive emtricitabine for as long as they continue to meet specific virologic criteria and until either: (1) the participant chooses to discontinue treatment of emtricitabine and withdraw from the rollover protocol; (2) the participant experiences a toxicity that necessitates the permanent discontinuation of emtricitabine, or (3) emtricitabine is approved for market distribution in the participant's country of residence.
Drug: Emtricitabine
6 mg/kg capsule once daily, up to a maximum dose of 200 mg once daily, or 10 mg/mL oral solution once daily, up to a maximum of 240 mg once daily
Number of Participants Who Had Access to, and Received the Intervention
This endpoint has been included to satisfy the requirements of ClinicalTrials.gov. However, there were no prespecified endpoints in this study.
Time frame: Up to 586 weeks
Participants were enrolled at 2 study sites in South Africa. The first participant was screened on 22 November 2005. The last study visit occurred on 13 February 2017.
| Milestone | Emtricitabine |
|---|---|
| Started | 50 |
| Completed | 9 |
| Not completed | 41 |
| Withdrew: Study medication non-compliance | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal from the study | 5 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Virologic failure | 8 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Rolled over to other gilead study | 23 |
| Withdrew: Participant relocated | 1 |
This endpoint has been included to satisfy the requirements of ClinicalTrials.gov. However, there were no prespecified endpoints in this study.
| Participants | Emtricitabine |
|---|---|
| Number of Participants Who Had Access to, and Received the Intervention | 50 |
Collected over Up to 586 Weeks + 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emtricitabine | 0/50 (0%) | 13/50 (26%) | 0/50 (0%) |
| Event | Emtricitabine |
|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 2/50 |
| AppendicitisInfections and infestations | 2/50 |
| Essential hypertensionVascular disorders | 1/50 |
| Femur fractureInjury, poisoning and procedural complications | 1/50 |
| Hand fractureInjury, poisoning and procedural complications | 1/50 |
| OverdoseInjury, poisoning and procedural complications | 1/50 |
| Weight decreasedInvestigations | 1/50 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/50 |
| AnaemiaBlood and lymphatic system disorders | 1/50 |
| NeutropeniaBlood and lymphatic system disorders | 1/50 |
Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug
| Age, Continuous(years) | Emtricitabine |
|---|---|
| Mean | 8 ± 2.5 |
| Sex: Female, Male(Participants) | Emtricitabine |
|---|---|
| Female | 24 |
| Male | 26 |
| Race/Ethnicity, Customized(Participants) | Emtricitabine |
|---|---|
| Black | 49 |
| Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2005 to primary completion in Feb 2017, 134 months.
Results were first posted in Apr 2018, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emtricitabine